PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial

Objectives Effective, well-tolerated therapies are needed for SLE.Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor under evaluation in phase 3 SLE studies.Deucravacitinib demonstrated superior efficacy vs placebo (PBO) in